The four molecules most often grouped as "next-generation GLP-1s" are not variations on one theme — they represent four separate strategic bets: add amylin (amycretin), optimise the GLP-1 backbone itself (ecnoglutide), abandon peptides entirely for an oral small molecule (orforglipron), or add glucagon (survodutide). If you are selecting a reference standard, the receptor target and the molecular class matter far more than the headline percentage attached to each name.
At a glance
| Candidate | Molecular class | Receptor target(s) | Route studied | Distinguishing feature |
|---|---|---|---|---|
| Amycretin | Unimolecular peptide | GLP-1 receptor + amylin/calcitonin receptor complexes | Subcutaneous and oral programmes | Two hormone systems in one chain rather than a co-formulation |
| Ecnoglutide | Long-acting GLP-1 peptide analog | GLP-1 receptor (cAMP-biased signalling reported) | Subcutaneous weekly | Signalling-bias engineering rather than a new receptor |
| Orforglipron | Non-peptide small molecule | GLP-1 receptor (partial agonist) | Oral, once daily | Not a peptide at all — no food or water restriction reported in trials |
| Survodutide | Acylated peptide dual agonist | GLP-1 receptor + glucagon receptor | Subcutaneous weekly | Strong hepatic signal in metabolic liver disease work |
Amycretin: one chain, two hormone systems
Amycretin is the most conceptually interesting of the four because it is unimolecular. Rather than co-formulating a GLP-1 analog with a separate amylin analog, the peptide is engineered so a single sequence engages both the GLP-1 receptor and the amylin/calcitonin receptor complexes. Early-phase data presented through 2025 reported substantial mean body-weight reductions at around 36 weeks in the highest study arms, with the usual early-phase caveats: small numbers, short duration, open questions on tolerability at the top of the range.
The research implication is that amycretin sits mechanistically adjacent to fixed-ratio combinations rather than replacing them. If your experiment is about whether amylin and GLP-1 signalling are additive at the receptor level, a co-formulation like semaglutide + cagrilintide lets you vary the ratio conceptually, while a unimolecular agent locks it. Research-grade amycretin is supplied as a lyophilised vial for that comparison work; the underlying amylin pharmacology is unpacked in the CagriSema and amylin analogs article.
Ecnoglutide: backbone optimisation, not a new target
Ecnoglutide (XW003) is a long-acting GLP-1 analog developed primarily in China, reported to be engineered toward cAMP-biased signalling at the GLP-1 receptor. The pitch is efficiency rather than novelty: the same receptor, engaged with a signalling profile intended to favour the pathway associated with metabolic effect over pathways associated with receptor internalisation. Phase-3 work in Chinese populations reported meaningful weight and glycaemic effects and has been the basis of regional regulatory filings.
For a research programme, ecnoglutide is most useful as a comparator that isolates one variable. Set against semaglutide in the same receptor assay, differences are attributable to backbone and acylation chemistry rather than to added receptor arms. Ecnoglutide research vials are supplied in 5 mg and 10 mg sizes for that purpose.
Orforglipron: the one that is not a peptide
Orforglipron is the outlier and deserves a different mental model. It is a non-peptide, orally bioavailable small-molecule agonist at the GLP-1 receptor, which means none of the peptide handling logic applies — no lyophilised cake, no reconstitution arithmetic, no counter-ion correction, no cold-chain anxiety. Trials have studied once-daily oral administration without the fasting and water-volume constraints that oral semaglutide tablets require, because absorption does not depend on a permeation enhancer.
That is the whole point of the molecule. If oral GLP-1 receptor pharmacology can be achieved with a manufacturable small molecule, the supply economics of the class change. In the laboratory, orforglipron research capsules behave like a conventional small-molecule reference compound; identity confirmation is a mass and chromatographic exercise rather than a peptide sequence exercise. It is worth contrasting with oral semaglutide research tablets, where the formulation, not the molecule, does the absorption work: the tablet relies on a permeation enhancer and strict fasting conditions to move a peptide across the gastric mucosa at all.
Survodutide: the glucagon bet
Survodutide (BI 456906) is an acylated peptide dual agonist at GLP-1 and glucagon receptors. Its most distinctive published signal is hepatic: phase-2 work in metabolic dysfunction-associated steatohepatitis reported a high proportion of participants meeting histological improvement endpoints, which is a different kind of result from a weight percentage. Phase-2 obesity work reported mean reductions in the high teens at around 46 weeks, and a phase-3 programme followed.
Glucagon receptor agonism is the shared feature between survodutide, mazdutide and the triple agonist retatrutide, which is why those three are usually studied together. The design trade-off — hepatic lipid mobilisation and energy expenditure against hepatic glucose output and heart rate — is the same in each. Survodutide vials are available in 5–20 mg sizes, and the direct comparison with the other dual agonist in the catalogue is in survodutide vs mazdutide.
How to choose a reference standard among them
Work backwards from the receptor question. If the question is amylin plus incretin additivity, amycretin and fixed-ratio amylin combinations are the relevant pair. If it is GLP-1 receptor signalling bias, ecnoglutide against semaglutide isolates it. If it is oral bioavailability without peptide chemistry, orforglipron is the only one of the four that answers it. If it is glucagon receptor contribution, survodutide is the cleanest dual-agonist probe because it has no GIP arm to confound the readout.
All four are investigational. None is approved in the United States, none of the clinical data attaches to research-grade lyophilised material, and all are supplied strictly for laboratory use. Class-level context sits in the GLP-1 and incretin collection, and the vocabulary is defined at dual agonist.